Събота 20 Апр 2019

Търсене в този сайт

Посетете ни във Фейсбук

Fasebook 

Многоезичен превод на сайта

Хостингът за проекта на този сайт е осигурен от СуперХостинг.БГ

Благодарим на СуперХостинг.БГ за подкрепата и спонсорство на уеб сайта ни! Асоциация Хипофиза

Препоръки за лечение на Акромегалията и Гигантизма - Литература

Рейтинг
УжаснаОтлична 
Share
        Литература

1. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, 
Veldhuis J, Wass J, Von
Werder K, Melmed S 2000 Criteria for cure of
acromegaly:a consensus statement. J Clin
Endocrinol Metab 85:526-9

2. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L,
 Grossman A,Ho K, Kleinberg D,
Lamberts S, Laws E, Lombardi G,
 Vance ML,Werder KV, Wass J, Giustina A 2002 Guidelines for
acromegaly management. J Clin Endocrinol Metab 87:4054-8

3. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA,
 Gaillard R, Ghigo E, Ho K, Jaquet
P, Kleinberg D, Lamberts S, 
Laws E,Lombardi G,Sheppard MC, Thorner M, Vance ML,Wass
 JA,
Giustina A 2005 Consensus statement: medical 
management of acromegaly. Eur JEndocrinol
153:737-40

4. Giustina A,Casanueva FF, Cavagnini F, Chanson P, Clemmons D
, Frohman LA, Gaillard R, Ho K
Jaquet P, Kleinberg DL, Lamberts
 SW,Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass J
A, Melmed S 2003 Diagnosis and treatment of acromegaly 
complications. J Endocrinol Invest 26:1242-7

5. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S 2008 Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820-838

6. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Jr., Montori VM 2008 Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266-81

7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ 2008 GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-6

8. Melmed S 2006 Medical progress: Acromegaly. N Engl J Med 355:2558-73

9. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-52

10. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP 2008 Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61-7

11. Holdaway IM, Bolland MJ, Gamble GD 2008 A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95

12. Swearingen B, Barker FG, 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-26

13. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-7

14. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F 2004 Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789-96

15. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P,Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-6

16. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF 2003 Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-72

17. Ludecke DK, Abe T 2006 Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations.Neuroendocrinology 83:230-9

18. Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152:379-87

19. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB 2001 Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86:1645-52

20. Shimon I, Cohen ZR, Ram Z, Hadani M 2001 Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48:1239-43; discussion 1244-5

21. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91

22. Ahmed E, Stratton P, Adams W 1999 Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 50:561-567

23. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM 1999 Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. Qjm 92:741-5

24. Bates PR, Carson MN, Trainer PJ, Wass JA 2008 Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf) 68:136-42

25. Frank G, Pasquini E 2006 Endoscopic cavernous sinus surgery with special reference to pituitary adenomas. In: Laws ER, Sheehan JP (eds) Pituitary surgery - a modern approach. Karger, Basel, pp 64-82

26. Abbassioun K, Amirjamshidi M, Mehrazin A, Khalatbary I, Keynama M, Bokai H, Abdollahi M 2006 A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years. Surg Neurol 66:26-31; discussion 31

27. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G 1997Effect of octreotide pretreatment on surgical 
outcome in acromegaly. J Clin Endocrinol Metab 82:3308-14

28. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignano T, Giovanelli M 2006 Presurgical treatment 
with somatostatin analogs in patients withacromegaly: effects on the remission and complication
 rates. J Neurosurg 104:899-906

29. Plockinger U, Quabbe HJ 2005 Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 147:485-93; discussion 493

30. Abe T, Ludecke DK 2001 Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137-45

31. Ben-Shlomo A, Melmed S 2003 Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. JClin Endocrinol Metab 88:963-8

32. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes- Socin H, Stevenaert A, Chanson P, Beckers A 2005 Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152:61-6

33. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R 2006 Partial surgical removal of growthhormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91:85-92

34. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA 2008 Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68:970-5

35. Hardy J 1973 Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO, Ross GT (eds) Diagnosis and treatment of pituitary tumors. Exerpta Medica, Amsterdam, pp 179-198

36. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentiallysuppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-92

37. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P 2007 Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67:282-9

38. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J 2007 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859-68

39. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-10

40. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G 2006 Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-403

41. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G 2006 Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112-8

42. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J 2008Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984-90

43. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ 2004 One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60:734-40

44. Bevan JS 2005 Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-63

45. Murray RD, Melmed S 2008 A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957-68

46. Neggers SJ, van Aken MO, de Herder WW, Feelders R A, Janssen JA, Badia X, Webb SM, van der Lely AJ 2008 Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93:3853-3859

47. Frohman LA, Bonert V 2007 Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 10:283-9

48. Parkinson C, Burman P, Messig M, Trainer PJ 2007 Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:190-5

49. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82

50. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ 2007 Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598-601

51. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-6

52. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-31

53. Bevan JS, Webster J, Burke CW, Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-40

54. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G 1997 Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518-23

55. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-8

56. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D 1998 Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139:516-21

57. Wagenaar AH, Harris AG, van der Lely AJ, Lamberts SW 1991 Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh) 125:637-42

58. Sadoul JL, Thyss A, Freychet P 1992 Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. Acta Endocrinol (Copenh) 126:179-83

59. Cremonini N, Graziano E, Chiarini V, Sforza A, Zampa GA 1992 Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995—bromocriptine combined treatment results. J Clin Endocrinol Metab 75:1166-9

60. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A 1999 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1:115-20

61. Cozzi R, Attanasio R, Lodrini S, Lasio G 2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209-15

62. Selvarajah D, Webster J, Ross R, Newell-Price J 2005 Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 152:569-74

63. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM 2008 Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348-56

64. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, 
Aris-Jilwan N, Houde G, Serri O 2008 Long-termcabergoline therapy is not associated with 
valvular heart disease in patients with prolactinomas. Pituitary

65. Webb SM, Badia X 2007 Quality of life in growth hormone deficiency and acromegaly. Endocrinol Metab Clin North Am 36:221-32

66. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P 2007 Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 92:1743-7

67. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J 2000 Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779-85

68. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA 2006 Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91:1239-45

69. Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM 2005 The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 62:210-6

70. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M 2003 Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 88:3105-12

71. Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, Conte- Devolx B, Regis J, Dufour H, Brue T 2005 Outcome of gamma kniferadiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90:4483-8

72. Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, Lisak R, Vymazal J, Pecen L 2006 Gamma knife radiosurgery for acromegaly--long-term experience. Clin Endocrinol (Oxf) 64:588-95

73. Pollock BE, Jacob JT, Brown PD, Nippoldt TB 2007 Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 106:833-8

74. Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML 2007 Gamma Knife surgery for Cushing's disease. J Neurosurg 106:980-7

75. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M 2004 Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151:439-46

76. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M 2005 Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90:800-4

77. Erfurth EM, Hagmar L 2005 Cerebrovascular disease in patients with pituitary tumors. Trends Endocrinol Metab 16:334-42

78. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-74

79. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A 2006 Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29:86-93

80. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ 2004 Increased prevalence ofregurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71-5

81. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A 2005 Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837-44

82. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E 2007 Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271-7

83. Bogazzi F, Cosci C, Sardella C, Costa A, Manetti L, Gasperi M, Rossi G, Bartalena L, Martino E 2006 Identification of acromegalic patients at risk of developing colonic adenomas. J Clin Endocrinol Metab 91:1351-6

84. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D 2007 AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399-409

85. Nemes A, Gavaller H, Csajbok E, Julesz J, Forster T, Csanady M 2008 Aortic stiffness is increased in acromegaly--a transthoracic echocardiographic study. Int J Cardiol 124:121-3

86. Coculescu M, Niculescu D, Lichiardopol R, Purice M 2007 Insulin resistance and insulin secretion in non-diabetic acromegalic patients. Exp Clin Endocrinol Diabetes 115:308-16

87. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M 2006 Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121-8

88. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegaliccardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-7

89. Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A 2006 Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 83:249-57

90. Strowski MZ, Parmar RM, Blake AD, Schaeffer JM 2000 Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111-7

91. Matano Y, Okada T, Suzuki A, Yoneda T, Takeda Y, Mabuchi H 2005 Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels. Am J Gastroenterol 100:1154-60

92. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C, Pfeiffer AF 2008 Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93:1254-62

93. Carmichael JD, Bonert VS, Mirocha JM, Melmed S 2008 The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab

94. Zirkzee EJ, Corssmit EP, Biermasz NR, Brouwer PA, Wiggers-De Bruine FT, Kroft LJ, Van Buchem MA, Roelfsema F, Pereira AM, Smit JW, Romijn JA 2004 Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery. J Clin Endocrinol Metab 89:4320-4

95. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C 2002 Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71

96. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA 2007 Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188:586-92

97. Vik-Mo EO, Oksnes M, Pedersen PH, Wentzel-Larsen T, Rodahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M 2007 Gamma knifestereotactic radiosurgery for acromegaly. Eur J Endocrinol 157:255-63

98. Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK 2008 Asia Pacific consensus recommendations for colorectal cancer screening. Gut 57:1166-76

99. Van Cutsem EJ, Oliveira J 2008 Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 19Suppl 2:ii29-30

100. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ 2008 Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134:1570-95